Article
Oncology
Edoardo Isnaldi, Francois Richard, Maxim De Schepper, Sophia Leduc, Marion Maetens, Tatjana Geukens, Karen Van Baelen, Ha-Linh Nguyen, Ghizlane Rouas, Gabriele Zoppoli, Fatima Cardoso, Christos Sotiriou, Denis Larsimont, Giuseppe Floris, Elia Biganzoli, Christine Desmedt
Summary: The impact of adiposity on the efficacy of endocrine treatment in patients with estrogen receptor positive breast cancer was investigated retrospectively. It was found that obesity and larger adipocyte diameter are associated with a higher likelihood of anti-proliferative response in neoadjuvant treatment.
Article
Oncology
Lucia Del Mastro, Mauro Mansutti, Giancarlo Bisagni, Riccardo Ponzone, Antonio Durando, Laura Amaducci, Enrico Campadelli, Francesco Cognetti, Antonio Frassoldati, Andrea Michelotti, Silvia Mura, Ylenia Urracci, Giovanni Sanna, Stefania Gori, Sabino De Placido, Ornella Garrone, Alessandra Fabi, Carla Barone, Stefano Tamberi, Claudia Bighin, Fabio Puglisi, Gabriella Moretti, Grazia Arpino, Alberto Ballestrero, Francesca Poggio, Matteo Lambertini, Filippo Montemurro, Paolo Bruzzi
Summary: The study showed that extending letrozole treatment to 5 years in postmenopausal patients with breast cancer who had received 2-3 years of tamoxifen resulted in a significant improvement in disease-free survival compared to the standard 2-3 years of letrozole treatment.
Article
Oncology
Davide Serrano, Sara Gandini, Parjhitham Thomas, Katherine D. Crew, Nagi B. Kumar, Lana A. Vornik, J. Jack Lee, Paolo Veronesi, Giuseppe Viale, Aliana Guerrieri-Gonzaga, Matteo Lazzeroni, Harriet Johansson, Mauro D'Amico, Flavio Guasone, Stefano Spinaci, Bjorn-Erik Bertelsen, Gunnar Mellgren, Isabelle Bedrosian, Diane Weber, Tawana Castile, Eileen Dimond, Brandy M. Heckman-Stoddard, Eva Szabo, Powel H. Brown, Andrea DeCensi, Bernardo Bonanni
Summary: This study compared different dosing schedules of exemestane, an aromatase inhibitor, in patients with breast cancer. The results showed that a 25mg dose taken three times weekly was as effective as a daily dose in decreasing serum estradiol levels, suggesting that this alternative schedule warrants further investigation.
Article
Oncology
Bora Lim, David A. Potter, Mohamad A. Salkeni, Paula Silverman, Tufia C. Haddad, Frederic Forget, Ahmad Awada, Jean-Luc Canon, Michael Danso, Alain Lortholary, Hugues Bourgeois, Elizabeth Tan-Chiu, Sylvie Vincent, Brittany Bahamon, Kevin J. Galinsky, Chirag Patel, Rachel Neuwirth, E. Jane Leonard, Jennifer R. Diamond
Summary: The study evaluated the efficacy and safety of sapanisertib plus exemestane or fulvestrant in treating advanced/metastatic hormone receptor-positive breast cancer, showing certain clinical benefit for patients. The treatment demonstrated different efficacy in patients previously sensitive or resistant to exemestane.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Mitch Dowsett, Lucy Kilburn, Mothaffar F. Rimawi, C. Kent Osborne, Katherine Pogue-Geile, Yuan Liu, Samuel A. Jacobs, Melanie Finnigan, Shannon Puhalla, Andrew Dodson, Vera Martins, Maggie Cheang, Sophie Perry, Chris Holcombe, Nick Turner, Claire Swift, Judith M. Bliss, Stephen Johnston
Summary: In postmenopausal women with ER+/HER2(-) primary breast cancer, higher ER and PgR levels were associated with a greater chance of complete cell-cycle arrest, while higher Ki67, c-PARP, and CCNE1 levels were associated with a lower chance. Letrozole decreased CCND1 levels, but palbociclib showed a tendency to increase them. Ki67 recovery within 3-9 days after stopping palbociclib indicates incomplete suppression of proliferation during the off week.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Manuela Rabaglio, Zhuoxin Sun, Rudolf Maibach, Anita Giobbie-Hurder, Bent Ejlertsen, Vernon J. Harvey, Patrick Neven, Istvan Lang, Herve Bonnefoi, Andrew Wardley, Barbara Ruepp, Monica Castiglione, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Marco Colleoni, Beat Thurlimann, Meredith M. Regan
Summary: This study investigates cardiovascular events in breast cancer patients during treatment with different drugs and found that monotherapy with letrozole is associated with a higher risk of ischemic heart disease, while the use of tamoxifen increases the risk of thromboembolic events.
BREAST CANCER RESEARCH AND TREATMENT
(2021)
Article
Public, Environmental & Occupational Health
Pedro Acien, Irene Velasco, Maribel Acien
Summary: The study found that combination therapy with an aromatase inhibitor and levonorgestrel-releasing intrauterine device led to significant improvement in symptoms of endometriosis, but had mixed effects on CA-125 levels. Surgical treatment significantly reduced ultrasound findings and long-term recurrence of endometriomas.
Review
Biochemistry & Molecular Biology
Fulvio Borella, Stefano Fucina, Luca Mangherini, Stefano Cosma, Andrea Roberto Carosso, Jessica Cusato, Paola Cassoni, Luca Bertero, Dionyssios Katsaros, Chiara Benedetto
Summary: Epithelial ovarian cancer (EOC) is a leading cause of cancer-related death in women, and its treatment remains challenging with poor survival rates. While the role of hormone receptors (HRs) in EOC has been actively explored, the use of hormone therapy (HT) in treating these tumors is still not well-established. Available data mostly come from retrospective series and small early clinical trials, suggesting that HT may be beneficial in adjuvant therapy, maintenance therapy, or in cases of recurrent disease, particularly for certain subtypes of EOC.
Article
Multidisciplinary Sciences
Kaiyue Wang, Lu Shen, Wei Tian, Suzhan Zhang
Summary: This retrospective cohort study aimed to investigate the effect of endocrine therapy on serum lipids in premenopausal women with early breast cancer. The results showed that different types of endocrine treatments had varying effects on blood lipids, with some treatments improving lipid levels but also carrying certain risks.
SCIENTIFIC REPORTS
(2022)
Article
Oncology
Jiayu Wang, Li Cai, Yanqiu Song, Tao Sun, Zhongsheng Tong, Yuee Teng, Huiping Li, Quchang Ouyang, Qianjun Chen, Shude Cui, Yongmei Yin, Ning Liao, Qiang Sun, Jifeng Feng, Xiaojia Wang, Binghe Xu
Summary: This study aimed to compare the efficacy of exemestane and fulvestrant as first-line monotherapies for postmenopausal Chinese women with advanced ER+/HER2- breast cancer. The results showed that fulvestrant was superior to exemestane in terms of progression-free survival, objective response rate, and time to treatment failure, with similar safety profiles.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Dane Fritzsche, Amy Indorf, Abby Miske, Kalyan Banda
Summary: Exemestane, a steroidal aromatase inhibitor, is an important therapeutic option for post-menopausal hormone receptor positive breast cancer, with rare incidence of hepatotoxicity. This report presents a case of cholestatic liver injury induced by exemestane. The patient switched to anastrozole after discontinuing exemestane without recurrence of symptoms.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2021)
Article
Obstetrics & Gynecology
Nathalie Soderhamn Bulow, Sven Olaf Skouby, Agnieszka Katarzyna Warzecha, Hanne Udengaard, Claus Yding Andersen, Marianne Dreyer Holt, Marie Louise Grondahl, Anders Nyboe Andersen, Negjyp Sopa, Anne Lis Englund Mikkelsen, Anja Pinborg, Nicholas Stephen Macklon
Summary: The use of letrozole during ovarian stimulation for IVF did not significantly decrease the proportion of women with premature progesterone levels above 1.5 ng/ml at the time of triggering final oocyte maturation. However, letrozole did significantly increase the proportion of women with mid-luteal progesterone levels above 30 ng/ml.
HUMAN REPRODUCTION
(2022)
Article
Medicine, General & Internal
Adhari AlZaabi, Hafsa AlAmri, Ghadeer ALAjmi, Manhal Allawati, Fatema Muhanna, Ruqaia Alabri, Fatema AlBusaidi, Shaima AlGhafri, Abdulrahman A. Al-Mirza, Khalid Al Baimani
Summary: The study assessed the risk of endometrial pathologies in female breast cancer patients treated with tamoxifen and aromatase inhibitors at Sultan Qaboos University Hospital in Oman. The results showed that premenopausal patients did not have an increased risk of endometrial cancer with tamoxifen and letrozole treatment. Breast cancer patients on these medications may need pre-treatment endometrial evaluation and explanation of alarming symptoms to guide further surveillance.
CUREUS JOURNAL OF MEDICAL SCIENCE
(2021)
Article
Oncology
Abhijit Mazumdar, William M. Tahaney, Jamal L. Hill, Yun Zhang, Sumankalai Ramachandran, Jitesh Kawedia, Jing Qian, Alejandro Contreras, Michelle I. Savage, Lana A. Vornik, Shizuko Sei, Altaf Mohammed, Powel H. Brown
Summary: This study demonstrates that the mTOR inhibitor everolimus can effectively delay the formation of ER-negative mammary tumors and suppress the proliferation of normal mammary gland cells. These results provide support for the use of everolimus in clinical trials for the prevention of ER-negative breast cancer.
CANCER PREVENTION RESEARCH
(2022)
Article
Pharmacology & Pharmacy
Chanhyun Park, Ji-Haeng Heo, Sanica Mehta, Sola Han, Jennifer C. Spencer
Summary: This study aimed to estimate the impact of individual adjuvant endocrine therapy (AET) types on treatment efficacy and overall survival in breast cancer patients. The study found that the tamoxifen group had a faster decrease in adherence compared to anastrozole, letrozole, and exemestane, and higher adherence was associated with a lower risk of mortality.
CLINICAL DRUG INVESTIGATION
(2023)
Review
Oncology
Albrecht Stenzinger, Arndt Vogel, Ulrich Lehmann, Angela Lamarca, Paul Hofman, Luigi Terracciano, Nicola Normanno
Summary: Cholangiocarcinomas are a heterogeneous group of tumors with distinct genomic alterations. Next-generation sequencing is a powerful tool for identifying gene variants and guiding personalized treatment for patients with cholangiocarcinomas. Understanding the use of NGS in molecular profiling is crucial for healthcare professionals to optimize treatment outcomes.
CANCER TREATMENT REVIEWS
(2024)